Palantir's billings increased 50% YoY to $823 million in Q3 2024, showcasing efficient revenue conversion from contracts.

Stifel raised the firm’s price target on Valmont (VMI) to $382 from $360 and keeps a Buy rating on the shares. Global ...

Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...

With only a few weeks until the holidays, it’s now crunch time to get something under the tree for your friends and family.